Phase 1 Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients

PURPOSE: Sirolimus is the eponymous inhibitor of the mammalian target of rapamycin (mTOR); however, only its analogues have been approved as cancer therapies. Nevertheless, sirolimus is readily available, has been well-studied in organ transplant patients, and demonstrates efficacy in several precli...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Cohen, Ezra EW, Wu, Kehua, Hartford, Christine, Kocherginsky, Masha, Eaton, Kimberly Napoli, Zha, Yuanyuan, Nallari, Anitha, Maitland, Michael L, Fox-Kay, Kammi, Moshier, Kristin, House, Larry, Ramirez, Jacqueline, Undevia, Samir D, Fleming, Gini F, Gajewski, Thomas F, Ratain, Mark J
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4410974/
https://ncbi.nlm.nih.gov/pubmed/22872575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0110
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi